POSTOPERATIVE RADIOTHERAPY FOR SYNOVIAL SARCOMA OF THE HEAD AND NECK DURING PREGNANCY: CLINICAL AND TECHNICAL MANAGEMENT AND FETAL DOSE ESTIMATES

Ester Orlandi1, Giancarlo Zonca2, Emanuele Pignoli2, Claudio Stucchi2, Marta Borroni2, Paola Collini3, Giulio Cantù4, Paolo G. Casali5, Federica Grosso5, Annamaria Cerrotta1, Carlo Fallai1, and Patrizia Olmi1

Departments of 1Radiation Oncology 1 & 2, 2Medical Physics, 3Pathology, 4Maxillofacial Surgery, 5Medical Oncology C (Sarcoma Unit), Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy

Key words: fetal dose, oral cavity, pregnancy, radiation therapy, synovial sarcoma.

Aims and background: In vivo and phantom dosimetry is reported to estimate the fetal dose and evaluate the effectiveness of a special shielding device to reduce fetal exposure in a woman undergoing postoperative radiation therapy for synovial oral cavity sarcoma at the 30th week of pregnancy.

Methods: In vivo measurements were performed by placing thermoluminescent dosimeters on 3 points for fetal dose estimation: uterine fundus, umbilicus and pubis. A Rando anthropomorphic phantom was used to simulate radiotherapy. We also performed off-axis dose measurements for wedged beams to estimate the dose contribution of this accessory used in the treatment.

Results: The special shielding device reduced the fetal dose by 70% on average, despite the presence of wedges, which increased the dose by a factor of about 2.5. Before delivery the patient received 48 Gy, and from the in vivo measurements a fetal dose of 8.5, 1.7 and 0.7 cGy was estimated to the uterine fundus, umbilicus and pubis, respectively.

Conclusions: Pre-treatment simulation in the same irradiation conditions is the only reliable approach to predict the fetal dose. By using a special shielding device, radiotherapy can be optimized while keeping the fetal exposure below the risk of deterministic damage.

Correspondence to: Dr Ester Orlandi, Department of Radiation Oncology 1, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milano, Italy. Tel +39-02-23903265; fax +39-02-23902472; e-mail ester.orlandi@istitutotumori.mi.it

Received February 22, 2006; accepted August 23, 2006.